Future-proofing Quality Control for Industrial Scale Cell and Gene Therapy Manufacture with Phacilitate and CGCT

Future-proofing Quality Control for Industrial Scale Cell and Gene Therapy Manufacture

A recorded panel discussion from Advanced Therapies connect, lead by Cell and Gene Therapy Catapult

As increasing numbers of advanced therapies enter large-scale production and supply for clinical trials, there is increasing emphasis on ensuring that QC strategies are able to accommodate the higher throughput and larger batch releases required for commercial-scale manufacture of these novel treatments and their components.

This panel explores the holistic approaches that innovators are taking to future proof and expand the UK’s QC capacity and capability to meet demand and provide the skills required for the sector to expand. The panellists also explore the future of next-generation analytics including real-time release testing and process analytical technologies and evaluating how we can address these industry-wide challenges.

Panellists:
  • James Miskin, Chief Technical Officer, Oxford Biomedica
  • Owen Bain, Head of ATMP Quality Control, Centre of Cell, Gene and Tissue Therapeutics, Royal Free Hospital
  • Markus Gerschater, Chief Scientific Officer, Synthace
  • Damian Marshall, Director, New Technologies, Cell and Gene Therapy Catapult

BACK TO MEMBER ZONE